.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Chubb
Express Scripts
US Department of Justice
Healthtrust
Cantor Fitzgerald
Argus Health
Covington
Novartis
McKinsey

Generated: September 23, 2017

DrugPatentWatch Database Preview

PARLODEL Drug Profile

« Back to Dashboard

What is the patent landscape for Parlodel, and what generic Parlodel alternatives are available?

Parlodel is a drug marketed by Us Pharms Holdings I and is included in one NDA.

The generic ingredient in PARLODEL is bromocriptine mesylate. There are nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.

Summary for Tradename: PARLODEL

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list36
Clinical Trials: see list7
Patent Applications: see list4,612
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PARLODEL at DailyMed

Pharmacology for Tradename: PARLODEL

Ingredient-typeErgolines
Drug ClassErgot Derivative
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Pharms Holdings I
PARLODEL
bromocriptine mesylate
CAPSULE;ORAL017962-002Mar 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
Us Pharms Holdings I
PARLODEL
bromocriptine mesylate
TABLET;ORAL017962-001Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PARLODEL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharms Holdings I
PARLODEL
bromocriptine mesylate
CAPSULE;ORAL017962-002Mar 1, 1982► Subscribe► Subscribe
Us Pharms Holdings I
PARLODEL
bromocriptine mesylate
TABLET;ORAL017962-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Us Pharms Holdings I
PARLODEL
bromocriptine mesylate
TABLET;ORAL017962-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Us Pharms Holdings I
PARLODEL
bromocriptine mesylate
CAPSULE;ORAL017962-002Mar 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Citi
Cantor Fitzgerald
Harvard Business School
Boehringer Ingelheim
Express Scripts
UBS
US Army
Queensland Health
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot